來凱醫藥－Ｂ (2105.HK)

7.840 +0.400 (+5.38%) 市場開市。 截至 10:29AM HKT。

來凱醫藥－Ｂ

3-2-467, 5 Xingbin Road
Lin Li Center Sino-Italy Ningbo Ecological Park
Yuyao
China

https://www.laekna.com

版塊: Healthcare
行業: Biotechnology
全職員工: 89

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Xiangyang Lu Ph.D.	CEO & Executive Chairman	2.91M	無	1965
Mr. Kwok Keung Chau ACCA, C.F.A., HKICPA	Chief Financial Officer	195.45k	無	1976
Ms. Ling Xie	Senior VP of Head of Operation & Executive Director	2.48M	無	1972
Dr. Xiang-Ju Gu Ph.D.	Executive Director & Chief Scientific Officer	2.66M	無	1967
Mr. Yong Yue	Chief Medical Officer	無	無	1962
Mr. Chenyu Ke	Joint Company Secretary	無	無	無
Ms. Wing Nga Ho	Joint Company Secretary	無	無	1972

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, and LAE120 for the treatment of cancer; LAE103 and LAE123 to treat muscle atrophy diseases; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China.

公司管治

截至 無 止，來凱醫藥－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。